{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:09:00Z","timestamp":1756382940061,"version":"3.44.0"},"reference-count":40,"publisher":"BMJ","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2007,6]]},"abstract":"<jats:p>Around 1.5% of adults in Europe and the USA have urge urinary incontinence (involuntary leakage immediately preceded or accompanied by urgency).1<jats:sup>,<\/jats:sup>2 This is usually due to overactive bladder syndrome (defined as urgency, with or without urge incontinence, and usually with frequency and nocturia),1 which occurs in around 12% of adults, and is similarly prevalent in men and women.2 We last reviewed this condition in 2001.3 Since then, two new antimuscarinic drugs, \u25bcdarifenacin (Emselex) and \u25bcsolifenacin (Vesicare) have been licensed in the UK for urge incontinence and\/or increased urinary frequency and urgency (as may occur in patients with overactive bladder syndrome),4<jats:sup>,<\/jats:sup>5 as have \u25bctransdermal oxybutynin (Kentera) and modified-release formulations of tolterodine (Detrusitol XL) and propiverine (Detrunorm XL).6\u20138 Here we review the place of these newer drugs and formulations.<\/jats:p>","DOI":"10.1136\/dtb.2007.45644","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T16:15:40Z","timestamp":1216397740000},"page":"44-48","source":"Crossref","is-referenced-by-count":1,"title":["Update on drugs for overactive bladder syndrome"],"prefix":"10.1136","volume":"45","member":"239","published-online":{"date-parts":[[2007,6,1]]},"reference":[{"key":"2025082722175698000_45.6.44.1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"2025082722175698000_45.6.44.2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"2025082722175698000_45.6.44.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"2025082722175698000_45.6.44.4","unstructured":"Emselex Summary of product characteristics, UK. Novartis Europharm Limited, September 2005."},{"key":"2025082722175698000_45.6.44.5","unstructured":"Vesicare Summary of product characteristics, UK. Astellas Pharma Limited, September 2005."},{"key":"2025082722175698000_45.6.44.6","unstructured":"Kentera Summary of product characteristics, UK. Nicobrand Limited, July 2004."},{"key":"2025082722175698000_45.6.44.7","unstructured":"Detrusitol XL Summary of product characteristics, UK. Pharmacia Limited, August 2005."},{"key":"2025082722175698000_45.6.44.8","unstructured":"Detrunorm XL Summary of product characteristics, UK. Amdipharm Plc, August 2006."},{"key":"2025082722175698000_45.6.44.9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0090-4295(97)00595-5","article-title":"The overactive bladder: Pharmacologic basis of drug treatment.","volume":"50","author":"Andersson K-E","year":"1997","journal-title":"Urology"},{"key":"2025082722175698000_45.6.44.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00595-5"},{"key":"2025082722175698000_45.6.44.11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.02.024","article-title":"The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"2025082722175698000_45.6.44.12","unstructured":"National Institute for Health and Clinical Excellence. 2006 Urinary incontinence [online]. Available: http:\/\/guidance.nice.org.uk\/CG40 [Accessed 17 May 2007]."},{"key":"2025082722175698000_45.6.44.13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder.","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"key":"2025082722175698000_45.6.44.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.01.008"},{"key":"2025082722175698000_45.6.44.15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00192-005-1340-3","article-title":"Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.","volume":"17","author":"Hill","year":"2006","journal-title":"Int Urogynecol J"},{"key":"2025082722175698000_45.6.44.16","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1464-410X.2006.06439.x","article-title":"Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.","volume":"98","author":"Haab","year":"2006","journal-title":"BJU Int"},{"key":"2025082722175698000_45.6.44.17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00345-005-0507-3","article-title":"Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.","volume":"23","author":"Zinner","year":"2005","journal-title":"World J Urol"},{"key":"2025082722175698000_45.6.44.18","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1464-410X.2005.05454.x","article-title":"A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int"},{"key":"2025082722175698000_45.6.44.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05454.x"},{"key":"2025082722175698000_45.6.44.20","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000140729.07840.16"},{"key":"2025082722175698000_45.6.44.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04606.x"},{"key":"2025082722175698000_45.6.44.22","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"2025082722175698000_45.6.44.23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2005.06.007","article-title":"Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.","volume":"48","author":"Abrams","year":"2005","journal-title":"Eur Urol"},{"key":"2025082722175698000_45.6.44.24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","article-title":"Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.","volume":"4","author":"Wagg","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"2025082722175698000_45.6.44.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2006.03.004"},{"key":"2025082722175698000_45.6.44.26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1185\/030079905X74907","article-title":"Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.","volume":"22","author":"Millard","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2025082722175698000_45.6.44.27","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X74907"},{"key":"2025082722175698000_45.6.44.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66095-8"},{"key":"2025082722175698000_45.6.44.29","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64684-8"},{"key":"2025082722175698000_45.6.44.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(03)00356-X"},{"key":"2025082722175698000_45.6.44.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"2025082722175698000_45.6.44.32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomised, double blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"2025082722175698000_45.6.44.33","doi-asserted-by":"publisher","DOI":"10.4065\/78.6.687"},{"key":"2025082722175698000_45.6.44.34","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04468.x"},{"key":"2025082722175698000_45.6.44.35","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000570"},{"key":"2025082722175698000_45.6.44.36","doi-asserted-by":"publisher","DOI":"10.1159\/000096338"},{"key":"2025082722175698000_45.6.44.37","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","article-title":"Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial.","volume":"171","author":"Zinner","year":"2004","journal-title":"J Urol"},{"key":"2025082722175698000_45.6.44.38","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000127742.73136.0c"},{"key":"2025082722175698000_45.6.44.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.08.017"},{"key":"2025082722175698000_45.6.44.40","unstructured":"Joint Formulary Committee. 2007 British National Formulary Edition 53. London: Royal Pharmaceutical Society of Great Britain and British Medical Association."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2007.45644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:18:11Z","timestamp":1756358291000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2007.45644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,6,1]]},"published-print":{"date-parts":[[2007,6]]}},"alternative-id":["10.1136\/dtb.2007.45644"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2007.45644","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}